Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Mar 30;381(9872):1099-106.
doi: 10.1016/S0140-6736(12)61687-0. Epub 2013 Jan 28.

Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial

Collaborators, Affiliations
Randomized Controlled Trial

Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial

Aaron M Milstone et al. Lancet. .

Abstract

Background: Bacteraemia is an important cause of morbidity and mortality in critically ill children. Our objective was to assess whether daily bathing in chlorhexidine gluconate (CHG) compared with standard bathing practices would reduce bacteraemia in critically ill children.

Methods: In an unmasked, cluster-randomised, two-period crossover trial, ten paediatric intensive-care units at five hospitals in the USA were randomly assigned a daily bathing routine for admitted patients older than 2 months, either standard bathing practices or using a cloth impregnated with 2% CHG, for a 6-month period. Units switched to the alternative bathing method for a second 6-month period. 6482 admissions were screened for eligibility. The primary outcome was an episode of bacteraemia. We did intention-to-treat (ITT) and per-protocol (PP) analyses. This study is registered with ClinicalTrials.gov (identifier NCT00549393).

Findings: 1521 admitted patients were excluded because their length of stay was less than 2 days, and 14 refused to participate. 4947 admissions were eligible for analysis. In the ITT population, a non-significant reduction in incidence of bacteraemia was noted with CHG bathing (3·52 per 1000 days, 95% CI 2·64-4·61) compared with standard practices (4·93 per 1000 days, 3·91-6·15; adjusted incidence rate ratio [aIRR] 0·71, 95% CI 0·42-1·20). In the PP population, incidence of bacteraemia was lower in patients receiving CHG bathing (3·28 per 1000 days, 2·27-4·58) compared with standard practices (4·93 per 1000 days, 3·91-6·15; aIRR 0·64, 0·42-0·98). No serious study-related adverse events were recorded, and the incidence of CHG-associated skin reactions was 1·2 per 1000 days (95% CI 0·60-2·02).

Interpretation: Critically ill children receiving daily CHG bathing had a lower incidence of bacteraemia compared with those receiving a standard bathing routine. Furthermore, the treatment was well tolerated.

Funding: Sage Products, US National Institutes of Health.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: Drs. Milstone, Perl, Zerr, Coffin, Song, Elward received grant support from Sage Products, Inc.. Dr. Milstone has received grant support from BioMerieux Inc.. Dr. Zerr has received grant support from Vioguard, Ltd. Dr. Perl has received grant support from Merck and is on an advisory board for Pfizer and Hospira. Dr. Song has received grant support from Optimer Pharmaceuticals. No other authors reported any conflicts.

Figures

Figure 1
Figure 1
Study profile. Ten intensive care units were randomized to either CHG bathing or standard bathing practices during the First Period and switched to the alternative bathing procedure during Period 2.
Figure 2
Figure 2
Change in crude incidence of bacteremia and CLABSI for per protocol population. Each line represents one unit and the slope of the line represents the change in incidence of bacteremia or CLABSI observed between control and treatment periods. Arrows represent the assignment change from period 1 to period 2 (e.g. an arrow pointing to CHG side of the graph implies that the unit in question was assigned to the CHG arm in Period 2 and the control arm in Period 1 – the assignment started as control and moved to CHG). The thick line represents the overall crude incidence rates comparing the control and CHG units. Units are identified for easy reference to supplemental table 7.

Comment in

  • Rethinking infection prevention research.
    Toltzis P, Goldmann D. Toltzis P, et al. Lancet. 2013 Mar 30;381(9872):1078-9. doi: 10.1016/S0140-6736(12)61996-5. Epub 2013 Jan 28. Lancet. 2013. PMID: 23363665 No abstract available.

References

    1. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271(20):1598–1601. - PubMed
    1. Edwards JR, Peterson KD, Mu Y, et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control. 2009;37(10):783–805. - PubMed
    1. Elward AM, Hollenbeak CS, Warren DK, Fraser VJ. Attributable cost of nosocomial primary bloodstream infection in pediatric intensive care unit patients. Pediatrics. 2005;115(4):868–872. - PubMed
    1. Armenian SH, Singh J, Arrieta AC. Risk factors for mortality resulting from bloodstream infections in a pediatric intensive care unit. Pediatr Infect Dis J. 2005;24(4):309–314. - PubMed
    1. Gray J, Gossain S, Morris K. Three-year survey of bacteremia and fungemia in a pediatric intensive care unit. Pediatr Infect Dis J. 2001;20(4):416–421. - PubMed

Publication types

MeSH terms

Associated data